MbrlCatalogueTitleDetail

Do you wish to reserve the book?
Heterogeneity in Bronchial-pulmonary Carcinomas: Immunohistochemical and Molecular Characterization
Heterogeneity in Bronchial-pulmonary Carcinomas: Immunohistochemical and Molecular Characterization
Hey, we have placed the reservation for you!
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
You are currently in the queue to collect this book. You will be notified once it is your turn to collect the book.
Oops! Something went wrong.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Heterogeneity in Bronchial-pulmonary Carcinomas: Immunohistochemical and Molecular Characterization
Oops! Something went wrong.
Oops! Something went wrong.
While trying to remove the title from your shelf something went wrong :( Kindly try again later!
Title added to your shelf!
Title added to your shelf!
View what I already have on My Shelf.
Oops! Something went wrong.
Oops! Something went wrong.
While trying to add the title to your shelf something went wrong :( Kindly try again later!
Do you wish to request the book?
Heterogeneity in Bronchial-pulmonary Carcinomas: Immunohistochemical and Molecular Characterization
Heterogeneity in Bronchial-pulmonary Carcinomas: Immunohistochemical and Molecular Characterization

Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
How would you like to get it?
We have requested the book for you! Sorry the robot delivery is not available at the moment
We have requested the book for you!
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Heterogeneity in Bronchial-pulmonary Carcinomas: Immunohistochemical and Molecular Characterization
Heterogeneity in Bronchial-pulmonary Carcinomas: Immunohistochemical and Molecular Characterization
Dissertation

Heterogeneity in Bronchial-pulmonary Carcinomas: Immunohistochemical and Molecular Characterization

2015
Request Book From Autostore and Choose the Collection Method
Overview
Lung cancer is still one of the most frequent cancers in the world, with a high mortality rate. Bronchial-pulmonary carcinomas are still undergoing morphological, immunohistochemical and genetic characterization, with important clinical implications. The characterization of preneoplastic lesions may bring a better understanding of carcinogenesis. Bronchial-pulmonary carcinomas and preneoplastic lesions of epidermoid carcinoma were studied using immunohistochemical and molecular pathology techniques, on a morphological pattern-based approach. Basal cell origin was proposed for preneoplastic epidermoid carcinoma lesions, where Ki67, p53 and EGFR constitute biomarkers of agressiveness. EGFR amplification is not the main mechanism for overexpression in preneoplastic lesions. High EGFR gene copy number and EGFR overexpression may play a role in epidermoid carcinoma carcinogenesis. EGFR mutations are rare. Epidermoid carcinomas with solid, large or clear cell phenotype or with CK7 or Vimentin (EMT phenotype) expression should be submitted to EGFR mutational analysis. Expression differences between adenocarcinoma patterns reinforce the importance of pattern classification due to their implications for diagnosis, pathogenic understanding and therapeutic outcome. There was higher expression of the gene products studied in adenocarcinomas compared to normal tissue, reinforcing their importance in adenocarcinoma carcinogenesis. Non-smoking female adenocarcinomas were diagnosed in earlier stages and showed higher ERCC1 expression. Advanced stages (IIA and IIIA) adenocarcinomas were characterized by higher Ki67, APC, ERCC1 expressions and lower TTF1 expression, reflecting more mitotically aggressive adenocarcinomas and a possible non-TRU origin. Solid patterns showed lower expression of nuclear TTF1 and higher expression of Ki67, reflecting aggressive biological behaviour, to be reported to clinicians avoiding poorly differentiated carcinoma reports. TTF1 provides significant guidance for therapy concerning lung adenocarcinoma as EGFR mutations were more frequent in TTF1 positive TRU-type adenocarcinomas. On the other hand TTF1 negative adenocarcinomas, some representing non-TRU adenocarcinomas are less prone to harbour EGFR mutations. Three clusters of adenocarcinoma patterns were identified: 1 – papillary; 2 – solid; and 3 – lepidic/BA, acinar and micropapillary. Molecular markers related to therapy resistance were explored and were found to demonstrate higher MRP1 and LRP expression in adenocarcinomas, indicating acquisition of drug-resistance mechanisms during carcinogenesis. Micropapillary, solid and also lepidic patterns showed ERCC1 expression indicating a capacity for Cisplatin-adducts removal. EGFR mutations were generally present in all the patterns of the same adenocarcinoma reinforcing mutational evaluation in small biopsies. Complex EGFR mutations and KRAS and EGFR mutations coexistence were detected, demonstrating molecular complexity. FGFR1 protein expression was present in the majority of the bronchial-pulmonary carcinomas, and is higher in adenocarcinomas and pleomorphic carcinomas. Higher expression in pleomorphic carcinomas may reflect the importance of FGFR1 controlling EMT pathways. FGFR1 amplification is identified in adenocarcinomas (14.7%), epidermoid carcinomas (20.8%), adenosquamous carcinoma (25%) and pleomorphic carcinomas (30%), without significant differences. Although FGFR1 amplification has been observed more frequently in epidermoid carcinomas than in adenocarcinomas, these results suggest that the other histological types harbouring FGFR1 amplification, such as adenosquamous, pleomorphic carcinomas, adenocarcinomas and even small cell lung carcinoma, may benefit from targeted therapy. Bronchial-pulmonary carcinomas have particular biological, clinical and therapeutic implications. The importance of precise pathological diagnosis, adenocarcinoma patterns recognition, and bronchial-pulmonary carcinogenesis related to biomarker predictive value for targeted therapy is highlighted.
Publisher
ProQuest Dissertations & Theses
ISBN
9798607323783